Long-acting Ocular Drug Delivery Technologies Addressing Unmet Needs in Ophthalmology
Guest Editor:
Professor Thakur Raghu Raj Singh
Chair in Pharmaceutics,
Founder & CTO Re-Vana Therapeutics,
McClay Research Centre, School of Pharmacy,
Queen's University Belfast, United Kingdom
Long-acting drug delivery (LADD) systems for ocular therapies see an increased interest in current research due to their capacity to decrease the need for repeated treatments. For example, patients with chronic ocular diseases, including glaucoma, age-related macular degeneration and diabetic retinopathy, require frequent administration of therapeutics in the form of either invasive intravitreal injections or eye drops. LADD systems can achieve prolonged therapeutic drug concentrations in target ocular tissues whilst improving patient adherence to therapy and limiting systemic exposure and side effects.
This special issue is intended to cover the latest developments and challenges perceived by different types of LADD-based systems (e.g., micro/nanoparticles, preformed implants, gels, depot forming systems, devices, contact lenses etc.) in the form of original research and reviews articles.
Potential topics for consideration include but are not limited to the following:
- The underlying challenges in the design of LADD-based systems
- Formulation and characterisation of a range of LADD-based formulations such as nano/microparticles, depot-forming gels, contact lenses, microneedles, biodegradable implants, non-degradable implants, and medical devices
- Regulatory challenges in the design of LADD-based system for ocular application
- Novel methods for in vitro and ex vivo testing LADD systems
- Safety, biocompatibility and biodegradation evaluations of LADD systems
- Preclinical assessment of LADD systems in healthy and disease animal models
Please submit your article for the special issue is by March 31, 2022.
Journal of Ocular Pharmacology and Therapeutics, the Official Journal of Association for Ocular Pharmacology and Therapeutics, and The International Symposium on Ocular Pharmacology & Therapeutics, is the only peer-reviewed journal that combines the fields of ophthalmology and pharmacology to enable optimal treatment, prevention, and diagnosis of ocular diseases and disorders. The Journal is under the editorial leadership of Editor-in-Chief Dr. Uday B. Kompella, University of Colorado Anschutz Medical Campus, and other leading investigators. View the entire editorial board.
Benefits of publishing with Journal of Ocular Pharmacology and Therapeutics:
- Latest Impact Factor: 2.671
- Indexed in PubMed/MEDLINE, PubMed Central, Scopus, among other leading indexing services
- Fast and user-friendly electronic submission
- Efficient and constructive peer review
- Prompt online publication
- High global visibility: accessible in 170 countries worldwide
- Open Access options available
To begin your submission, log into ManuscriptCentral, select “Ocular Drug Delivery Tech Special Issue” from the drop-down menu, and enter JOP21ODD2MC to waive the manuscript submission fee. Please note that this waiver only applies to the submittal fee.
Visit the Journal's website to view more information for authors including manuscript guidelines, information on available author services, and publication costs.
Contact the Editorial Office with any questions you may have.